title: A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.
abstract: Hepatitis C virus (HCV) infection continues to disproportionately affect incarcerated populations. New HCV drugs present opportunities and challenges to address HCV in corrections. The goal of this study was to evaluate the impact of the treatment costs for HCV infection in a state correctional population through a budget impact analysis comparing differing treatment strategies. Electronic and paper medical records were reviewed to estimate the prevalence of hepatitis C within the Rhode Island Department of Corrections. Three treatment strategies were evaluated as follows: (1) treating all chronically infected persons, (2) treating only patients with demonstrated fibrosis, and (3) treating only patients with advanced fibrosis. Budget impact was computed as the percentage of pharmacy and overall healthcare expenditures accrued by total drug costs assuming entirely interferon-free therapy. Sensitivity analyses assessed potential variance in costs related to variability in HCV prevalence, genotype, estimated variation in market pricing, length of stay for the sentenced population, and uptake of newly available regimens. Chronic HCV prevalence was estimated at 17% of the total population. Treating all sentenced inmates with at least 6 months remaining of their sentence would cost about $34 million-13 times the pharmacy budget and almost twice the overall healthcare budget. Treating inmates with advanced fibrosis would cost about $15 million. A hypothetical 50% reduction in total drug costs for future therapies could cost $17 million to treat all eligible inmates. With immense costs projected with new treatment, it is unlikely that correctional facilities will have the capacity to treat all those afflicted with HCV. Alternative payment strategies in collaboration with outside programs may be necessary to curb this epidemic. In order to improve care and treatment delivery, drug costs also need to be seriously reevaluated to be more accessible and equitable now that HCV is more curable.
authors.affiliation: Brown University School of Public Health, Providence, RI, USA.
authors.forename: John T
authors.initials: JT
authors.lastname: Nguyen
authors.forename: Josiah D
authors.initials: JD
authors.lastname: Rich
authors.forename: Bradley W
authors.initials: BW
authors.lastname: Brockmann
authors.forename: Fred
authors.initials: F
authors.lastname: Vohr
authors.forename: Anne
authors.initials: A
authors.lastname: Spaulding
authors.forename: Brian T
authors.initials: BT
authors.lastname: Montague
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D002017:Budgets; D016527:Drug Costs / Q000706:statistics & numerical data; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011329:Prisoners / Q000706:statistics & numerical data; D011330:Prisons / Q000191:economics* / Q000706:statistics & numerical data; D012237:Rhode Island / Q000453:epidemiology; D013219:State Government; D055815:Young Adult
chemical_list: D000998:Antiviral Agents
references.citation: Top Antivir Med. 2013 Feb-Mar;21(1):27-35
references.pmid: 23596276
references.citation: Am J Public Health. 2005 Oct;95(10):1739-40
references.pmid: 16186452
references.citation: Aliment Pharmacol Ther. 2015 Mar;41(6):544-63
references.pmid: 25619871
references.citation: Lancet. 1997 Mar 22;349(9055):825-32
references.pmid: 9121257
references.citation: Prev Med. 1999 Jan;28(1):92-100
references.pmid: 9973592
references.citation: Lancet. 2014 Nov 15;384(9956):1756-65
references.pmid: 25078309
references.citation: Clin Infect Dis. 2008 Oct 1;47(7):952-61
references.pmid: 18715156
references.citation: Hepatology. 2014 Apr;59(4):1246-9
references.pmid: 24493069
references.citation: Ann Intern Med. 2014 Oct 21;161(8):546-53
references.pmid: 25329202
references.citation: Public Health Rep. 2007;122 Suppl 2:83-8
references.pmid: 17542460
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S30-4
references.pmid: 12407574
references.citation: J Viral Hepat. 2008 Nov;15(11):797-808
references.pmid: 18637074
references.citation: J Clin Gastroenterol. 2009 Aug;43(7):686-91
references.pmid: 19295448
references.citation: Ann Intern Med. 2003 Feb 4;138(3):187-90
references.pmid: 12558357
references.citation: Liver Int. 2014 Feb;34 Suppl 1:79-84
references.pmid: 24373082
references.citation: Hepatology. 2013 Oct;58(4):1215-24
references.pmid: 23504650
references.citation: Liver Int. 2014 Feb;34 Suppl 1:18-23
references.pmid: 24373074
references.citation: J Hepatol. 2014 Apr;60(4):691-8
references.pmid: 24291324
references.citation: N Engl J Med. 2013 May 16;368(20):1859-61
references.pmid: 23675657
references.citation: Public Health Rep. 2009 Jan-Feb;124(1):120-6
references.pmid: 19413034
references.citation: Am J Gastroenterol. 2004 May;99(5):866-72
references.pmid: 15128352
references.citation: Fam Pract Manag. 2008 Jul-Aug;15(7):A3-8
references.pmid: 18763679
references.citation: N Engl J Med. 2013 May 16;368(20):1878-87
references.pmid: 23607594
references.citation: N Engl J Med. 2014 May 15;370(20):1871-4
references.pmid: 24827032
references.citation: MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):357-61
references.pmid: 23657111
references.citation: Am J Public Health. 2004 Jul;94(7):1218-23
references.pmid: 15226146
references.citation: J Urban Health. 2014 Apr;91(2):376-82
references.pmid: 23722268
references.citation: Am J Gastroenterol. 2009 Apr;104(4):1024-31
references.pmid: 19240708
references.citation: Clin Infect Dis. 2013 May;56(10):1382-93
references.pmid: 23392392
references.citation: Hepatology. 2009 Apr;49(4):1335-74
references.pmid: 19330875
references.citation: N Engl J Med. 2014 Apr 24;370(17):1594-603
references.pmid: 24720703
references.citation: N Engl J Med. 2014 May 22;370(21):1983-92
references.pmid: 24795200
references.citation: MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32
references.pmid: 22895429
references.citation: BMC Public Health. 2010 Dec 21;10:777
references.pmid: 21176146
references.citation: Top Antivir Med. 2013 Feb-Mar;21(1):15-9
references.pmid: 23596274
references.citation: J Psychoactive Drugs. 2008 Dec;40(4):493-501
references.pmid: 19283953
references.citation: Liver Int. 2011 Sep;31(8):1090-101
references.pmid: 21745274
references.citation: Value Health. 2007 Sep-Oct;10(5):336-47
references.pmid: 17888098
references.citation: Ann Intern Med. 2003 Feb 4;138(3):235-6
references.pmid: 12558365
references.citation: Am J Public Health. 2013 Aug;103(8):1445-9
references.pmid: 23763404
references.citation: N Engl J Med. 2013 May 16;368(20):1867-77
references.pmid: 23607593
references.citation: N Engl J Med. 2014 Jan 16;370(3):211-21
references.pmid: 24428467
references.citation: Am J Public Health. 2010 Jan;100(1):13-7
references.pmid: 20007626
references.citation: Clin Infect Dis. 2012 Jul;55 Suppl 1:S49-53
references.pmid: 22715214
references.citation: N Engl J Med. 2014 May 15;370(20):1889-98
references.pmid: 24725239